VX-702
Cat. No.：YN350034
CAS No. ：745833-23-2
| 产品名称: | VX-702 |
| CAS No.: | 745833-23-2 |
| Chemical Name: | 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide |
| Synonyms: | vx 702 |
| 分子量: | 404.32 |
| 分子式: | C₁₉H₁₂F₄N₄O₂ |
| SMILES: | O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | VX-702是 p38α MAPK 选择性抑制剂，选择性是p38β MAPK 的 14 倍。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Goldstein, D.M., Kuglstatter, A., Lou, Y., et al.Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disordersJ. Med. Chem.53,2345-2353(2010)
Kuliopulos, A., Mohanlal, R., and Covic, L.Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregationThromb. Haemost.92,1387-1393(2004)
Damjanov, N., Kauffman, R.S., and Spencer-Green, G.T.Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studiesArthritis Rheum.60(5),1232-1241(2009)
